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Approaches to the treatment of endometriosis vary worldwide, but studies comparing endometriosis medications
in different ethnic groups are rare. A systematic literature search identified two studies directly comparing
dienogest (DNG) versus gonadotropin-releasing hormone (GnRH) analogues in European and Japanese populations.
Meta-analysis of visual analogue scale scores revealed no heterogeneity in response between the trials, indicating
equivalent efficacy of DNG and GnRH analogues for endometriosis-related pain across populations. DNG was
significantly superior to GnRH analogues for bone mineral density change in both trials, but significant
heterogeneity between the studies may indicate ethnic differences in physiology.
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Endometriosis is a chronic, painful disease caused by the
growth of endometrial-like tissue outside the uterus, which
induces a chronic inflammation resulting in fibrosis, adhe-
sion formation, and scarring around the abdominal cavity
and organs [1,2]. Endometriosis is common, occurring in
approximately 10% of women of reproductive age [3],
although the exact prevalence remains unknown because
invasive procedures are required to confirm the diagnosis.
Limited evidence suggests that the prevalence of endomet-
riosis may vary with ethnicity. A slightly higher prevalence
is reported in Japanese and other Asian women, and a
lower incidence among African women, when compared to
Caucasians [4-7]. Ethnic variations in prevalence could
result from divergence in a range of genetic and environ-
mental risk factors, which are thought to underlie the de-
velopment of this complex condition [8-12]. Regardless of
ethnicity, the symptoms of endometriosis are highly va-
riable between individual women and often overlap those
of other conditions. In many women, the symptoms are
severe and quality of life can be greatly reduced [13-15].
Treatment approaches vary widely between regions
worldwide, reflecting in part the availability of approved
medications and divergences in surgical practice. In* Correspondence: christoph.gerlinger@bayer.com
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reproduction in any medium, provided the orJapan, for example, gonadotropin-releasing hormone
(GnRH) analogues appear to be widely used [16], while pro-
gestins account for a relatively small proportion of treat-
ment regimens [17]. In other parts of the world, combined
oral contraceptives and non-steroidal anti-inflammatory
drugs are widely prescribed for relief of endometriosis-
related pain, despite limitations in the supportive trial evi-
dence, and the androgen, danazol, is still used in a number
of countries despite its unpleasant side effects [18].
Progestins have been prescribed for the treatment of
endometriosis for a number of decades, although the avail-
ability and actual use of approved progestins vary markedly
between regions. The older progestins, in particular, may
cause side effects (e.g. acne, hair growth and weight gain)
that are associated with non-specific binding to androgenic
and glucocorticoid receptors, and which may limit compli-
ance with long-term treatment [19]. Newer generation pro-
gestins tend to have greater specificity for the progesterone
receptor and offer favourable tolerability profiles [20,21].
Whether ethnic differences in response contribute to
the variability in treatment approaches worldwide has
been little studied. Research in this field is mainly
restricted to small clinical pharmacology studies [22].
Large-scale clinical trials or meta-analyses comparing
the efficacy and safety of medications in different ethnic
groups are rare. Interestingly, two 24-week trials with
similar designs were recently published comparing the
efficacy and safety of the progestin dienogest (DNG)al Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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women with endometriosis [23,24].
The aim of this paper is to provide a literature review
of existing studies comparing DNG against GnRH ana-
logues, and to explore, by meta-analysis, the results from
these trials to investigate whether the treatment effects
of DNG were similar or divergent between the European
and Japanese populations.
Treatments compared in this meta-analysis
The GnRH analogues are widely recognised as an effective
treatment for endometriosis. Agents in this class act by
modifying the release of follicle-stimulating hormone (FSH)
and luteinising hormone (LH), thereby suppressing ovarian
estradiol production. As endometriosis is an estrogen-
dependent disease, this approach typically results in relief
of symptoms; however, due to the potent suppression of
endogenous estrogen production, GnRH analogues are
associated with hypoestrogenic symptoms and loss of bone
mass, limiting their use to short-term therapy or requiring
add-back therapy [25].
DNG is a selective oral progestin that has recently
received approval as monotherapy at a dose of 2 mg daily
for the treatment of endometriosis in Europe, Japan, and
other regions based on two independent, preclinical and
clinical trial programmes conducted in Europe and Japan
[26-33]. These clinical programmes included dose-ranging,
placebo-controlled and active comparator-controlled stu-
dies of DNG, with study durations of up to 15 months.
Literature search methodology
Based on an awareness of these studies, a systematic
literature search was performed to identify potential
additional relevant studies comparing DNG against GnRH
analogues in endometriosis. A search of publications in
PubMed using keywords including ‘endometriosis’, ‘dieno-
gest’ and ‘gonadotropin-releasing hormone analogue or
‘GnRH analogue’ retrieved 11 publications [23,24,34-42],
four of which were classified as ‘clinical trials’. Two of these
trials were excluded from further analysis because they
reported subpopulations of one of the remaining articles
[41] or they included a different patient population by fo-
cusing on postsurgical consolidation treatment in women
with endometriosis [39]. As a result, two trials qualified for
inclusion in the meta-analysis.
A wider literature search for other approved medica-
tions in endometriosis identified no similarly designed,
prospective trials that would permit a comparison of
outcomes by meta-analysis in different ethnic groups.
The two DNG studies were both multicentre, rando-
mised, 24-week trials to compare the efficacy and safety
of DNG against a GnRH analogue in the treatment of
endometriosis. Two hundred and fifty-two women from
17 centres in Europe were randomised to receive DNG(1 × 2 mg/day, orally) or leuprolide acetate (3.75 mg, 4-
weekly intramuscular injection) [23], and 271 women from
24 centres in Japan received DNG (2 × 1 mg/day, orally) or
buserelin acetate (3 × 300 μg/day, intranasally) [24]. Once-
daily dosing of DNG was investigated in the European
trial programme because of its potential for enhanced
compliance. The European trial had an open-label design,
while the Japanese trial was conducted double-blind.
Inclusion and exclusion criteria were broadly similar for
both trials. Inclusion criteria included painful symptoms
associated with endometriosis, confirmed by laparoscopy
or laparotomy, in women aged 18 to 45 years (European
trial) or aged 20 years or above (Japanese trial). Women
who were pregnant or breast feeding, had used hormonal
agents within specified times prior to the trial, had ab-
normal gynaecological examination findings (other than
endometriosis) or who had risk factors for decreased bone
mineral density (BMD) were excluded. Completion rates
were greater than 85% in each treatment group in both
trials [23,24].
Self-reported endometriosis-related pain (on a 0 to
100 mm visual analogue scale [VAS]) [43] was used as
the primary assessment of efficacy in both trials, in line
with current practice which recognises pain reduction as
the most relevant treatment objective in women with
endometriosis [44]. BMD (g/cm2) of the lumbar spine,
measured by dual energy X-ray absorptiometry at
selected study centres, was included as a safety outcome
in both trials [23,24].
Meta-analysis methodology
The current analyses focused on one quantitative measure
of efficacy (i.e. VAS score) and one measure of safety (i.e.
BMD), respectively. Efficacy analyses were performed on
the primary per-protocol population in each trial (as appro-
priate for non-inferiority studies), and analyses of BMD
included the eligible subset of women for whom data were
available at both screening and final visit.
For each efficacy and safety outcome, the following
methodology was employed. Changes in outcome from
baseline to week 24 were combined for the two trials in
fixed-effect meta-analyses, assuming an equal effect size
[45]. The treatment difference between DNG and the
GnRH analogue in each trial was used as the effect mea-
sure. The more powerful estimate of effect size of treat-
ment gained from the combined trial results was used to
extend and confirm the individual trial outcomes.
Heterogeneity across trials was described using the I²
index [46] and tested using the Q-statistic [45]. The in-
verse variance method was used to weight the trials,
based on the contribution of patient numbers and ran-
dom variation (standard deviation [SD]). The two GnRH
analogues studied were assumed to be equivalent to each
other in efficacy and safety.
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of R software [47] and version 1.5.0 of the R software ‘meta’
package [48].Meta-analysis results
The women in the European and Japanese trials were of
similar average age, while the European women had a
slightly greater average body weight (Table 1).Efficacy analysis (VAS change for endometriosis-related
pain)
As previously reported, both trials concluded that DNG is
non-inferior to the respective GnRH analogue for reduction
of endometriosis-associated pain, based on VAS change.
In the European population, VAS change for pel-
vic pain (mean± SD) from baseline to week 24
was −47.5 ± 28.8 mm for DNG and −46.0 ± 24.8 mm
for the GnRH analogue (Figure 1) [23]. In the
Japanese trial, VAS change for lower abdominal pain
from baseline to week 24 was −30.2 ± 31.8 mm for
DNG and −27.3 ± 33.8 mm for the GnRH analogue
(Figure 1) [24].
Mean treatment differences between DNG and the
GnRH analogue were −1.50 mm (95% confidence interval
[CI]: –9.25 to 6.25) in the European trial and −2.90 mm
(95% CI: –10.99 to 5.19) in the Japanese population (both
favouring DNG) (Figure 2). No heterogeneity between trial
outcomes was apparent (Q-statistic = 0.06; P=0.8065; 1 df;
I² = 0%), suggesting that the effect of DNG for pain reduc-
tion, when compared with the respective GnRH analogue,
was similar in the two populations.
Using the inverse variance method, the European trial
had a weight of 52.17% and the Japanese trial had a weight
of 47.83% in the meta-analysis. The lower weighting for the
Japanese trial was due to a higher SD in VAS score change,
despite providing 253 (57.63%) of the 439 women.
As the mean treatment difference in the Japanese trial
was −2.90 mm compared to −1.50 mm for the European
population, the inverse variance method for weighting
provided a slightly smaller estimate of combined effect
than weighting the trials equally. The combined estimateTable 1 Baseline characteristics of the European and Japanes
European population [23]
DNG (n=120) GnRH analo
Age (years, mean± SD) 30.6 ± 6.2 31.0 ± 5.8
Weight (kg, mean± SD) 62.5 ± 10.8 62.7 ± 9.6
Lumbar BMD (g/cm2, mean± SD) 1.06 ± 0.1 (n= 26) 1.07 ± 0.1 (n
DNG, dienogest (2 mg/day); GnRH, gonadotropin-releasing hormone analogue; BMD
3.75 mg intramuscular injection, four-weekly; Japanese trial, buserelin acetate 3 × 30of the fixed effect model was −2.17 mm in favour of
DNG (95% CI: –7.77 to 3.43) (Figure 2).Safety analysis (BMD change)
Both the European and Japanese trials reported that the
study medications were generally well tolerated and that
rates of premature withdrawals due to adverse events
were low (≤ 5%). Hot flushes were more common in the
GnRH analogue than the DNG group in both trials, while
uterine bleeding was more common in the DNG group, as
may be expected of a medication in the progestin class.
DNG was significantly superior to the GnRH analogue
with respect to change in lumbar BMD in both trials, i.e.
causing no or less reduction in BMD [23,24]. In the
European trial, in women whose measurements were
available at both screening and final visit (n= 50), mean
(± SD) BMD increased 0.25 ± 2.77% in the DNG group,
versus a reduction of 4.04 ± 4.84% in the GnRH analogue
group (P= 0.0003) (Figure 3) [23]. Respective changes in
BMD in the Japanese trial were −1.00 ± 2.30% in the
DNG group and −2.60 ± 2.30% in the GnRH analogue
group (P= 0.003) (Figure 3) [24].
The meta-analysis showed a treatment difference be-
tween DNG and the GnRH analogue of 4.29 (95% CI: 2.17
to 6.41) in European women and 1.60 (95% CI: 0.63 to
2.57) in Japanese women (both favouring DNG) (Figure 4).
Significant heterogeneity between the trials was seen with
respect to change in BMD (Q-statistic =5.11; P=0.0238; 1
df; I² = 80.4%).
The Japanese trial had a weight of 82.78% and the
European trial had a lower weight of 17.22% due to the
different sample sizes and variances (inverse variance
method). No combined estimate was calculated due to
the heterogeneity of the trials.Discussion
The global variability in standard approaches to the
treatment of endometriosis could, in theory, reflect a
number of influences, including divergent symptomato-
logies, variation in the range of approved medications
available and variable treatment responses among differ-
ent ethnic groups. The findings of our analysis indicatee trial populations (full analysis sets)
Japanese population [24]
gue (n=128) DNG (n=128) GnRH analogue (n=125)
33.5 ± 6.9 33.8 ± 6.2
52.1 ± 7.1 53.3 ± 8.2
= 31) 1.04 ± 0.1 (n= 41) 1.03 ± 0.1 (n= 46)
, bone mineral density. GnRH analogues: European trial, leuprolide acetate
0 μg/day, intranasally.
Figure 1 Mean (± SEM) change in VAS (mm) between baseline and week 24 in the European [23] and Japanese [24] trials of DNG
versus GnRH analogue.
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lar in the two populations investigated.
DNG had similar benefits for pain reduction after
24 weeks of treatment in each population, with mean
VAS changes of −47.5 mm and −30.2 mm in European
and Japanese women, respectively. The treatment group
differences were −1.50 and
−2.90 mm in favour of DNG, respectively, in the indi-
vidual trials, and were −2.17 mm in favour of DNG in
the combined meta-analysis. When assuming a non-
inferiority margin of 10 mm, as suggested by Gerlinger
et al [43], these combined findings confirm the equiva-
lent efficacy of DNG and GnRH analogues with regard
to reduction of pain.
For the safety assessment, DNG showed significant be-
nefits over the GnRH analogue in the change in lumbar
BMD in each population [23,24]. These findings for DNG
are in broad agreement with the results of Momoeda et alFigure 2 Meta-analysis of change in pelvic pain measured on a VAS (
GnRH analogue.[29], who conducted a 1-year study of DNG treatment in
a Japanese population. In this long-term study, a special
focus was placed on BMD evaluation before, during and
after treatment with DNG. BMD decreased by 1.6 ± 2.4%
at 24 weeks and 1.7 ± 2.2% at 52 weeks, which the authors
suggested reflects, in part, the normal decrease of BMD
expected during ageing, with no relevant contribution
from DNG [29].
Although DNG was significantly superior to the
respective GnRH analogue for the change in BMD in
both trials, there was heterogeneity between the trials in
the size of this effect. This heterogeneity could be
explained by a number of causes relating to ethnicity.
The Japanese population had a slightly lower mean base-
line BMD than their European counterparts (Table 1), in
agreement with published data suggesting that Asian
women have lower natural BMD [49]. Ethnic differences
in physiological estrogen levels have also been reported,mm) in the European [23] and Japanese [24] trials of DNG versus
Figure 3 Mean (± SEM) of percent change in BMD between baseline and week 24 in the European [23] and Japanese [24] trials of DNG
versus GnRH analogue.
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compared with Caucasians [50]. Estrogen plays a role in
the maintenance of bone health, and deficiency during
either growth or ageing may lead to reduced BMD and
increased bone fragility [51]. Compared to Caucasians,
Asian women with estrogen deficiency are more likely to
have BMD below the expected range for age [52]. Diffe-
ring natural levels of estrogen throughout the lives of
the European and Japanese populations studied may,
therefore, have contributed to heterogeneity in the
response to DNG and/or GnRH analogue treatment.
The two GnRH analogues investigated may also poten-
tially be associated with differential effects on BMD. There
appears to be no published literature that directly compares
leuprolide acetate and buserelin acetate in endometriosis,
but a review by the Cochrane Collaboration [25] suggests
that, in similar trials, 24 weeks of treatment with buserelin
acetate was associated with twice the BMD loss that was
seen with leuprolide acetate [53,54]. However, these trials
were conducted in different ethnic groups and the methods
used for BMD analysis differed.Figure 4 Meta-analysis of per cent change in BMD in the European [2Limitations to this meta-analysis include the subtle dif-
ferences in trial design (open-label versus blinded) and the
different GnRH analogues (leuprolide acetate and buse-
relin acetate) used in the two trials. Additional informa-
tion on demographics and lifestyle (dietary habits, level of
exercise, etc.) of the participants may have provided fur-
ther insights relevant to data interpretation.
Conclusions
Treatment regimens for endometriosis vary widely between
regions and it is unclear whether these different approaches
reflect a difference in treatment response among ethnic
groups. The availability of similar trials comparing DNG to
GnRH analogues in European and Japanese women with
endometriosis permits a comparison of the efficacy and
safety outcomes in these ethnic groups. This meta-analysis
suggests that women in Europe and Japan respond
similarly in terms of pain relief to two of the main
approved treatment options for endometriosis: DNG
and GnRH analogues. Heterogeneity between the popu-
lations in BMD change requires exploration but may3] and Japanese [24] trials of DNG versus GnRH analogue.
Gerlinger et al. BMC Women's Health 2012, 12:9 Page 6 of 7
http://www.biomedcentral.com/1472-6874/12/9potentially be explained by differences in physiology or
in response to therapy.
These results indicate that current differences in treat-
ment patterns between regions may not be based on a
medical rationale but on historical reasons or even
chance. The findings support efforts to develop inter-
nationally agreed treatment guidelines in endometriosis
that are applicable across populations.
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